****

**M-ERA.NET Call 2022**

***Pre-Proposal***

***Project Acronym:***

***Project Coordinator:***

***(Organisation and Country):***

**Each partner is requested to contact the respective national/regional funding organisation before Pre-Proposal submission**

*To be completed by the Project Coordinator only.*

*The Pre-Proposal form has a technical limit of 22 pages.*

*Refer to Guide for Proposers when filling out this form.*

*The following formatting conditions apply:*

*The minimum font size should be 11 points. Standard character spacing and a minimum of single line spacing is to be used. Text elements other than the body text, such as headers, foot/end notes, captions, formulas, may deviate, but must be legible. The page size is A4, and all margins (top, bottom, left, right) should be at least 15 mm (not including any footers or headers).*

*.*

**Content:**

[1. SUMMARY 2](#_Toc96689507)

[2. CONSORTIUM OVERVIEW Attention: PIC is Mandatory 5](#_Toc96689508)

[3. PROJECT DESCRIPTION 6](#_Toc96689509)

[3.1 Excellence 6](#_Toc96689510)

[3.1.1. Objectives of the project and expected results 6](#_Toc96689511)

[3.1.2 Relevance of the objectives to the call text (topic) 6](#_Toc96689512)

[3.1.3 Concept and approach 6](#_Toc96689513)

[3.1.4 Ambition 6](#_Toc96689514)

[3.1.5 Resposible Research & Innovation (RRI) 6](#_Toc96689515)

[3.2. Impact 6](#_Toc96689516)

[3.2.1 Contribution at the European or international level to the expected impacts listed under the selected topic of the call 6](#_Toc96689517)

[3.3 Implementation 7](#_Toc96689518)

[3.3.1. Work plan 7](#_Toc96689519)

[3.3.2 Consortium description 7](#_Toc96689520)

[3.3.3. Inter- and transdisciplinarity 7](#_Toc96689521)

[3.3.4. Benefit of transnational cooperation for the consortium as a whole 7](#_Toc96689522)

[3.3.5. Cost Calculation 8](#_Toc96689523)

[4. ETHICAL ISSUES 8](#_Toc96689524)

[4.1. Environment, health and safety issues (EHS) 9](#_Toc96689525)

[4.2. Gender relevance 9](#_Toc96689526)

[5. CHECKLIST FOR PROPOSERS 10](#_Toc96689527)

# 1. SUMMARY

*Colour Code:*

*Black: text in black must be kept*

*Blue: text in blue is for information purpose and can be deleted.*

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Project Acronym** | | | | |  | | | | | | | | |
| **Project Long Title** | | | | |  | | | | | | | | |
| **Project Coordinator** | | | | | Name: | |  | | | | | | |
| E-mail: | |  | | | | | | |
| Coordinator Organisation  (full name in original language / name in English) | | | | | Original Language:  English: | | | Country/ Region | | |  | | |
| Address |  | | | | | | | Tel: | |  | | | |
| Fax: | |  | | | |
| Postal code (CEDEX) | | | | | |  |
| City | |  | | | | | www: | |  | | | |
| **Total Project Costs**  **(Euro)** | | | | |  | | **Requested Funding**  **(Euro)** | | | | |  | |
| Planned starting date | |  | | | | Duration  (in months) | |  | Total person months | | | |  |
| Call Topic | |  | | Materials for energy | | | | | | | | | |
|  | | Innovative surfaces, coatings and interfaces | | | | | | | | | |
|  | | High performance composites | | | | | | | | | |
|  | | Functional materials | | | | | | | | | |
|  | | New strategies for advanced material-based technologies in health applications | | | | | | | | | |
|  | | Materials for electronics | | | | | | | | | |

**Project Summary**

***Project Summary, including:*** *specific innovation objectives and results, needs addressed, impact and potential benefits (up to 4000 characters recommended). Whenever appropriate, indicate the TRL[[1]](#footnote-1) position in the beginning of the project and after the project is finished (not mandatory).*

**Relevance to funding programmes**

***(for each of the involved national/regional funding programme)***

Justify why the proposal is in line with the objectives of each funding programme and why the proposal includes the required national impact (up to 2 pages recommended).

# 2. CONSORTIUM OVERVIEW Attention: PIC is Mandatory

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **CONSORTIUM OVERVIEW** | | | | | | |
| **Organisation** | **Partner name (Full name)** | **Coordinator (P1)** | **Partner 2:** | **Partner 3:** | **Partner 4:** | **Partner 5:** |
| **Participation Identification Code (PIC) [[2]](#footnote-2)** |  |  |  |  |  |
| TRL[[3]](#footnote-3) at project start |  |  |  |  |  |
| TRL3 at project end |  |  |  |  |  |
| Organisation Type[[4]](#footnote-4) |  |  |  |  |  |
| Website (http:…) |  |  |  |  |  |
| Region / Country |  |  |  |  |  |
| Organisation registration number[[5]](#footnote-5) |  |  |  |  |  |
| Size (Employees) [[6]](#footnote-6) |  |  |  |  |  |
| Turnover (K€)5 |  |  |  |  |  |
| **Contact Person** | Title / Name |  |  |  |  |  |
| Telephone |  |  |  |  |  |
| E-mail |  |  |  |  |  |
| **Funding Organisation (FO)** | Name of FO +Contact person in in FO [[7]](#footnote-7) |  |  |  |  |  |
| Funding Programme (full name[[8]](#footnote-8)) |  |  |  |  |  |

# 3. PROJECT DESCRIPTION

*Describe the innovation of the project outcome(s), the originality of the proposed approach and the market needs (if applicable) addressed by the project. Please indicate the TRL at the beginning and at the end of the project.*

## 3.1 Excellence

## 3.1.1. Objectives of the project and expected results

## 3.1.2 Relevance of the objectives to the call text (topic)

## 3.1.3 Concept and approach

* *Overall concept*
* *Start and target TRL*

## 3.1.4 Ambition

* *Current state of art and progress beyond the state-of-the-art*
* *Originality and/or innovation of the proposed approach*

## 3.1.5 Responsible Research & Innovation (RRI)

* *Explain how the project will engage with the ethical, social, political, environmental or cultural dimensions of the proposed research (see Guide for Proposers Call, Annex 5 for more information).*

## 3.2. Impact

## 3.2.1 Contribution at the European or international level to the expected impacts listed under the selected call topic

* **Scientific impacts**

* **Economic impacts** (*for low TRLs present the visions for potential industrial use*)

* **Societal and environmental impacts**

## 3.3 Implementation

## 3.3.1. Work plan

* *Work package description: Title of each WP and short description*
* *Timing of the different work packages and their components (Gantt chart or similar)*

## 3.3.2 Consortium description

*Describe the role of each partner in the project and partner’s qualification in the field of proposal, including their past experiences and expertise (last 5 years).*

**Partner 1 (Coordinator):**

Role in the project:

Team qualification in the field of proposal:

**Partner 2:**

Role in the project:

Team qualification in the field of proposal:

**Partner 3:**

Role in the project:

Team qualification in the field of proposal:

*Please duplicate as needed*

## 3.3.3. Inter- and transdisciplinarity

*Describe the inter- and transdisciplinary character of the consortium, and the approach taken by the project to engage with external stakeholders / user groups*

## 3.3.4. Benefit of transnational cooperation for the consortium as a whole

*Explain the added value provided by the transnational cooperation (for the consortium and for each partner).*

## 3.3.5. Cost Calculation

**Total project costs per partner**

|  |  |  |  |
| --- | --- | --- | --- |
| **Partner** | **Person months** | **Total Costs** | **Requested Funding** |
|  | Euro | Euro |
| Partner 1 (Coordinator): |  |  |  |
| Partner 2: |  |  |  |
| Partner 3: |  |  |  |
| Partner 4: |  |  |  |
| Partner 5: |  |  |  |
| **Total:** |  |  |  |

# 4. ETHICAL ISSUES

*Please fill in YES or NO.*

| **ETHICAL ISSUES[[9]](#footnote-9)** | | **YES / NO** | **Page** |
| --- | --- | --- | --- |
| **HUMAN EMBRYOS/FOETUSES** | | | |
| Does your research involve Human Embryonic Stem Cells (hESCs)? | |  |  |
| Does your research involve the use of human embryos? | |  |  |
| **HUMANS** | | | |
| Does your research involve human participants? | |  |  |
| Does this activity involve interventions (physical also including imaging technology, behavioural treatments, etc.) on the study participants? | |  |  |
| Does this activity involve conducting a clinical study as defined by the Clinical Trial Regulation (EU 536/2014[[10]](#footnote-10))? (using pharmaceuticals, biologicals, radiopharmaceuticals, or advanced therapy medicinal products) | |  |  |
| **HUMAN CELLS / TISSUES** (not covered by section 1) | | | |
| Does your research involve human cells or tissues? | |  |  |
| **PERSONAL DATA** | | | |
| Does your research involve processing of personal data? | |  |  |
| Does it involve the processing of special categories of personal data (e.g. sexual lifestyle, ethnicity, genetic, biometric and health data, political opinion, religious or philosophical beliefs)? | |  |  |
| If YES | Does it involve processing of genetic, biometric or health data? |  |  |
| Does it involve profiling, systematic monitoring of individuals, or processing of large scale of special categories of data or intrusive methods of data processing (such as, surveillance, geolocation tracking etc.)? | |  |  |
| Does this activity involve further processing of previously collected personal data (including use of preexisting data sets or sources, merging existing data sets)? | |  |  |
| **ANIMALS** | | | |
| Does your research involve animals? | |  |  |
| **ENVIRONMENT, HEALTH and SAFETY** | | | |
| Does this activity involve the use of substances or processes that may cause harm to the environment, to animals or plants (during the implementation of the activity or further to the use of the results, as a possible impact)? | |  |  |
| Does this activity deal with endangered fauna and/or flora / protected areas? | |  |  |
| Does this activity involve the use of substances or processes that may cause harm to humans, including those performing the activity (during the implementation of the activity or further to the use of the results, as a possible impact)? | |  |  |
| **ARTIFICIAL INTELLIGENCE** | | | |
| Does this activity involve the development, deployment and/or use of Artificial Intelligence? | |  |  |
| **OTHER ETHICS ISSUES** | | | |
| Are there any other ethical issues that should be taken into consideration? | |  |  |
| *Please specify (max. 1000 characters)* | |  |  |

|  |  |
| --- | --- |
| **I CONFIRM that I have taken into account all ethics issues above.** |  |

## 4.1. Environment, health and safety issues (EHS)

*Describe the strategy for dealing with environment, health and safety issues (EHS)*

## 4.2. Gender relevance

*Please describe the gender relevance of your topic[[11]](#footnote-11) (if relevant) and the gender balance of the project consortium*

# 5. CHECKLIST FOR PROPOSERS

|  |  |
| --- | --- |
| The proposal conforms to the call guidelines. |  |
| Every project partner has been in direct contact with his/her national/regional funding agency and has checked that their collaboration and their project contributions are eligible for funding. |  |
| All project partners have checked the national/regional programme procedures and regulations. All project partners are aware of documents requested by the national/regional funding organisations.  ***IMPORTANT REMINDER: All consortium partners must check if applications (at Pre-Proposal and/or Full-Proposal stage) have to be submitted also to their national/regional funding organisations.*** |  |
| All partners who are not eligible for 100% funding are able to provide financial resources for their own contribution. |  |
| The consortium is aware that a duly signed and stamped consortium agreement (CA) between the project partners is recommended for funded projects based on national/regional funding rules, including agreements on intellectual property rights (IPR) and agreements on scientific publications. At the time of proposal submission it is recommended to provide the principles ruling the CA but not the CA itself. |  |

***Please go*** [***https://www.m-era.net/joint-call-2022***](https://www.m-era.net/joint-call-2022) ***to submit this pre-proposal form online.***

***Deadline for submission: 15 June 2022, 12:00 noon Brussels time***

***For further information on M-ERA.NET: please go to*** [***http://www.m-era.net***](http://www.m-era.net)

1. <https://ec.europa.eu/research/participants/data/ref/h2020/other/wp/2018-2020/annexes/h2020-wp1820-annex-g-trl_en.pdf> [↑](#footnote-ref-1)
2. Insert Participant Identification Code (PIC) of your organisation as used for participating on Horizon 2020. Further information on how to find / get your PIC see [FAQs](https://www.m-era.net/joint-calls/joint-call-2022/call2022-faq_v1-0-2.pdf) [↑](#footnote-ref-2)
3. Technology Readiness Level (see Annex 2 in the Guide for Proposers) [↑](#footnote-ref-3)
4. HE-University, RES-Research organisation, SME-Small Medium sized Enterprise, IND-Large Company, OTH-Others. (according to national rules) [↑](#footnote-ref-4)
5. VAT number or other Registration number [↑](#footnote-ref-5)
6. Only for companies [↑](#footnote-ref-6)
7. **It is strongly recommended to contact M-ERA.NET contact person in your region/country** for further information about funding rules, prior to the submission of a Pre-Proposal (see [Participating countries & regions Call 2022](https://www.m-era.net/joint-calls/joint-call-2022/participating-countries-regions-call-2022) ) [↑](#footnote-ref-7)
8. Name of the funding programme for which the partner is applying [↑](#footnote-ref-8)
9. Table assembled based on EC Horizon Europe Guidance: <https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/common/guidance/how-to-complete-your-ethics-self-assessment_en.pdf> [↑](#footnote-ref-9)
10. <https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX%3A32014R0536> [↑](#footnote-ref-10)
11. Please note that this question does not refer to gender balance in the teams in charge of carrying out the project but to the content of the planned research and innovation activities. Sex and Gender analysis refers to biological characteristics and social/cultural factors respectively.   
    See factsheet: European Commission, Directorate-General for Research and Innovation, Gendered innovations : how inclusive analysis contributes to research and innovation, Publications Office, 2020, <https://data.europa.eu/doi/10.2777/361142> [↑](#footnote-ref-11)